KCTD2

Across TCGA pan-cancer cohorts, KCTD2 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated KCTD2 data layer compared with 21 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in thyroid carcinoma (THCA), where higher KCTD2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated KCTD2 expression acts as an unfavorable survival marker.

THCA, LIHC, and UCEC are the cancer types where KCTD2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THCA	DFS	Median	All	0.049	0.828	<.001	18	view →
LIHC	DFS	Median	All	0.044	0.553	<.001	12	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

KCTD2–THCA (DFS)

Open the THCA breakdown →